Immunitybio vs Macrogenics
Macrogenics is the larger business, with $150m of revenue in fiscal 2025 against $113m for Immunitybio (1.3 times as much). Immunitybio grew faster (668.3% against -0.3%). Macrogenics kept more of each dollar of sales as profit: a net margin of -49.9% against -310.2%.
| Latest fiscal year | ImmunitybioIBRX, 2025 | MacrogenicsMGNX, 2025 |
|---|---|---|
| Revenue | $113m | $150m |
| Revenue growth | 668.3% | -0.3% |
| Net income | −$351m | −$74.6m |
| Operating margin | -226.0% | -48.7% |
| Net margin | -310.2% | -49.9% |
| Return on equity | — | -86.9% |
| Free cash flow | −$309m | −$83.0m |
| Cash | $88.3m | $57.2m |
| Total debt | $326m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 691 | 293 |
| Market value | $8.69bn | $149m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 29 (Weak) |
| Insider trades, 12 months | 0 buys, 16 sales | 0 buys, 1 sales |